Hepatology 2009 Current Perspectives on Chronic Liver Disease		(Recorded East Coast Satellite Broadcast Webcast)
			0.5 AMA PRA Category 1 Credits (Expires on June 22, 2010)
	Treatment of Genotype 1 Nonresponders		(Webcast)
	Presented by: Fred Poordad, MD		No CME credit available
	Treatment of Hepatitis C Genotype 1 Infected Patients		(Webcast)
	Presented by: Sammy Saab, MD		No CME credit available
	Optimizing Outcomes: Emerging Therapies for HCV		(Symposium Webcast)
	2006		No CME credit available

HCV 2009   New>  HCV Genotypes 2 & 3   New>  Approach to Patients that Failed to Achieve Sustained Viral Response New>  HCV Genotype 1             HCV Slide Archive             HCV 3rd Edition Slides Epidemiology and Natural History Diagnosis and Monitoring Treatment Special Populations   Overview   African Americans   Genotype 1   Hispanic Americans   Genotype 2/3   HCV/HIV Co-infected   Retreatment   HCV and Alcohol   Side Effects   Liver Transplant   Emerging Therapies   Acute Infection   HCV 2nd Edition Slides Epidemiology and Natural History Diagnosis and Monitoring Treatment Side Effects and Management Treatment Special Patient Populations       HCV - AASLD 2005     Emerging Therapies in HCV:'Building the Bridge to Improved Outcomes' Ribavirin Analogues   Immunomodulators   Caspase Inhibitors   Specific Small Molecule Inhibitors       HCV 1st Edition Slides Epidemiology and Natural History   Molecular Tools for the Diagnosis and Monitoring of Hepatitis C Treatment of HCV   Prevention of Coinfection/Superinfection   Early Assessment of Response   Histologic Response to Treatment   Adherence and SE Management

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C Gambarin-Gelwan M, Jacobson IM. J Viral Hepat 2008;9:623-33. Host Genetics, Steatosis and Insulin Resistance among African Americans and Caucasian Americans with Hepatitis C Virus Genotype-1 Infection Iuliano AD, Feingold E, Wahed AS, Kleiner DE, Belle SH, Conjeevaram HS, Zmuda J, Liang TJ, Yee LJ. Intervirology 2009;52:49-56. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection John G. McHutchison, M.D., Gregory T. Everson, M.D., Stuart C. Gordon, M.D., Ira M. Jacobson, M.D., Mark Sulkowski, M.D., Robert Kauffman, M.D., Lindsay McNair, M.D., John Alam, M.D., Andrew J. Muir, M.D., for the PROVE1 Study Team. N ENGL J Med 2009;360:1827-1838 Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection Christophe Hézode, M.D., Nicole Forestier, M.D., Geoffrey Dusheiko, M.D., Peter Ferenci, M.D., Stanislas Pol, M.D., Tobias Goeser, M.D., Jean-Pierre Bronowicki, M.D., Marc Bourlière, M.D., Shahin Gharakhanian, M.D., Leif Bengtsson, B.S.C., Lindsay McNair, M.D., M.P.H., Shelley George, M.D., Tara Kieffer, Ph.D., Ann Kwong, Ph.D., Robert S. Kauffman, M.D., Ph.D., John Alam, M.D., Jean-Michel Pawlotsky, M.D., Ph.D., Stefan Zeuzem, M.D., for the PROVE2 Study Team. N ENGL J Med 2009;360:1839-1850. Adherence to medication for chronic hepatitis C: Building on the model of human immunodeficiency virus antiretroviral adherence research Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D.Ailiment Pharmacol Ther. 2009 Mar 26 (Epub ahead of print) Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection Puchner KP, Berg T. Z Gastroenterol. 2009;47:446-456. Epub 2009 May 5. Neuropsychological performance in patients with human immunodeficiency (HIV) and neuropsychological hepatitis C virus (HCV) coinfection Failde J, Rodríguez Alvarez M, López Castro J, Simón López M. Neurologia. 2009;3:154-9. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rockstroh J, Coutinho R, Dore GJ, Dusheiko GM, Danta M. Gastroenterol. 2009;136:1609-17. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection Gonzalez SA, Fiel MI, Sauk J, Canchis PW, Liu RC, Chiriboga L, Yee HT, Jacobson IM, Talal AH. J Viral Hepat. 2009;2:141-8. Peginterferon alfa-2b and Ribavirin: Effective in Patients with Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonzales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; The Epic Study Group. Gasterenterol 2009;Jan 22 (Epub ahead of print) Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors Kwong AD, McNair L, Jacobson I, George S.Curr Opin Pharmacol 2008;5:522-31. Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study Loras C, Saro C, Gonzalez-Huix F, et al. Am J Gastroenterol 2009;104:57-63. Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon Di Bisceglie A, Shiffman M, Everson G, et al for the HALT-C Trial Investigators. N Engl J Med 2008;359:2429-2441. Exceeding the limits of liver histology markers Mehta S, Lau B, Afdhal N and Thomas D. J Hepatol 2009;50:36-41. A Randomized, Prospective Trial of Ribavirin 400 mg/Day Versus 800 mg/Day in Combination with Peginterferon Alfa-2a in Hepatitis C Virus Genotypes 2 and 3 Ferenci P, Brunner H, Laferl H, Scherzer T, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K, for the Austrian Hepatitis Study Group. HEPATOLOGY;47:1816-1823. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3 Poustchi H, Negro F, Hui J, Homer I, Cua Y, Brandt L, Kench J, George J. J Hepatol 2008;48:28-34. Combination of Oxidative Stress and Steatosis Is a Risk Factor for Fibrosis in Alcohol-Drinking Patients With Chronic Hepatitis C Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Am J Gastroenterol 2008;103:147-153. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C McHutchinson J, Dusheikko G, , Schiffman M, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon S, Campbell F, Theodore D, Blackman N, Jenkins J, Afdhal N for the TPL102357 Study Group. N ENGL J MED 357,22:2227-2236. Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1-Infected Slow Responders Pearlman B, Ehleben C, Saifee S. HEPATOLOGY 2007;6:1688-1694. Predictors of Response of U.S. Veterans to Treatment for the Hepatitis C Virus Backus LI, Boothroyd DB, Phillips BR, Mole LA. HEPATOLOGY 2007 ; 46:37-47. Telaprevir and Pegylated Interferon-alpha-2a Inhibit Wild-Type and Resistant Genotype 1 Hepatitis C Virus Replication in Patients Kieffer T, Sarrazin C, Miller J, Welker M, Forestier N, Reesink H, Kwong A, Zuezem S Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3 Schiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola´ R, Shafran SD, Barange K, Lin A, Sorman A, Zeuzem S, for the ACCELERATE Investigators. NEJM 2007 ; 357:124-134 Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication Huang J, Dai C, Hwang, Ho C, Hsiao P, Hsieh M, Lee L, Lin Z, Chen S, Hsieh M, Wang L, Shin S, Chang W, Chuang W, Yu M. Am J Gastroenterol 2007 ; 102:1237-1243 Cognitive Function Does Not Worsen During Pegylated Interferon and Ribavirin Retreatment of Chronic Hepatitis C Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok AS, Kronfol Z, Padmanabhan L, and the HALT-C Trial Group. HEPATOLOGY 2007 ; 45:1154-1163 The Effects of HCV Infection and Management on Health-Related Quality of Life Younossi Z, Kallman J, Kincaid J. HEPATOLOGY 2007;45:806-816 HCV RNA Detection by TMA during the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial C. Morishima et al. HEPTOLOGY, Vol. 44, No. 2, 2006:360-367 Impact of Disease Severity on Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons From the HALT-C Trial Everson G, Hoefs J, Seeff L, Bonkovsky H, Naishadham D, Schiffman M, Kahn J, Lok A, De Bisceglie, Lee W, Dienstag J, Ghany M, Morishima C, and the HALT-C Trial Group. HEPATOLOGY 2006 ; 44:1675-1684 Cost-Effectiveness of Hematologic Growth Factors for Anemia Occurring During Hepatitis C Combination Therapy R Del Rio, Anthony B. Post, Mendel Singer. Hepatology 2006; 44:1598-1606 Steatosis and Progression of Fibrosis in Untreated Patients With Chronic Hepatitis C Infection P. Perumalswami et al. HEP, Vol 43, No 4 (April 2006); 780-787 Treatment with daily concensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study M. Cornberg et al. Journal of Hepatology 44 (Feb 2006) 291-301 Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia S. Zeuzem et al J Hep 44 (January 2006) 97-103 Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse M Gerotto et al, J Hep 44 (January 2006) 83-87 HCV/Clinical: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin Ferenci P et al J Hep 43 (2005) 425-433. HCV/Clinical: Pilot study of interferon gamma for chronic hepatitis C A. Soza, T. Heller, M. Ghany, G. Lutchman, T. Liang, J. Germain, H. Hsu, Y. Park, J. Hoofnagle Journal of Hepatology 43 (2005) 67-71. HCV/Clinical: Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C WL Krawitt et al. J.Hep 43 (2005) 243-249 HCV/Clinical: Adult living donor liver transplantation: Who is the ideal donor and recipient? Henkie P et al. J Hep. Volume 43 (2005) 13-17